Articaine + Epinephrine

Generic name: Articaine hydrochloride + Epinephrine / Adrenaline

Category: Amide local anesthetic with ester side chain + vasoconstrictor

Common brand names: Septocaine, Septanest, Ubistesin, Ultracain, Orabloc. Brand availability, cartridge volume, and epinephrine concentration vary by country.

This article is for dental education only. Articaine with epinephrine should be used only by trained clinicians who understand dental local anesthesia, maximum-dose calculation, aspiration technique, intravascular injection risk, epinephrine precautions, and emergency management of local anesthetic systemic toxicity. Dose must be calculated by milligrams and body weight, not estimated casually by cartridge count alone.

Articaine with epinephrine is a widely used dental local anesthetic combination for infiltration anesthesia and nerve blocks. It is commonly supplied as a 4% solution with epinephrine 1:100,000 or 1:200,000.

Articaine is valued in dentistry because it often provides effective infiltration anesthesia, including in many mandibular situations, and epinephrine improves duration and local hemostasis.

The main safety concerns are local anesthetic systemic toxicity, accidental intravascular injection, excessive epinephrine effect, cardiovascular caution, and careful dose calculation because 4% articaine contains more anesthetic per cartridge than 2% lidocaine.

• Best use: dental local anesthesia when a vasoconstrictor is appropriate
• Common dental context: infiltrations, supplemental mandibular anesthesia, nerve blocks, restorative dentistry, endodontics, extractions, oral surgery
• Main advantage: effective anesthesia with good diffusion and improved hemostasis from epinephrine
• Main risks: toxicity, intravascular injection, paresthesia concern, palpitations, hypertension, cardiovascular caution
• Clinical priority: calculate dose, aspirate, inject slowly, and avoid unnecessary repeated cartridges

• Local infiltration anesthesia for restorative dental procedures
• Supplemental infiltration when mandibular anesthesia is difficult
• Nerve blocks for dental treatment when appropriate
• Endodontic treatment requiring pulpal anesthesia
• Periodontal procedures and soft-tissue manipulation
• Extractions and minor oral surgery
• Improved local hemostasis during procedures where bleeding control is helpful

Example only: A common dental formulation is articaine 4% with epinephrine 1:100,000 or 1:200,000. One 1.8 mL cartridge of 4% articaine contains about 72 mg articaine.

For healthy adults, the maximum recommended dosage commonly listed in product information is 7 mg/kg articaine. Some labels express this as 0.175 mL/kg for articaine with epinephrine formulations.

For a 70 kg healthy adult, 7 mg/kg equals 490 mg articaine. Since one 1.8 mL cartridge contains about 72 mg, this equals about 6.8 cartridges by articaine calculation. In real dental care, the practical limit may be lower because of epinephrine exposure, medical risk, procedure need, and clinical judgment.

Dose must always consider body weight, age, cardiovascular status, liver function, pregnancy, anxiety level, total cartridges, epinephrine concentration, aspiration result, injection site, and whether other local anesthetics were used.

• Known hypersensitivity to articaine or other amide local anesthetics
• Known hypersensitivity to sulfites when using epinephrine-containing cartridges that contain sulfite antioxidants
• Severe uncontrolled cardiovascular disease without medical guidance
• Recent myocardial infarction, unstable angina, serious uncontrolled arrhythmia, or severe uncontrolled hypertension without medical approval
• Severe liver disease or significantly impaired local anesthetic metabolism requiring dose reduction or medical input
• Use beyond maximum safe dose or without ability to manage toxicity
• Injection into a blood vessel or unsafe technique
• Use in very young pediatric patients where local product information does not support safety

• Local anesthetic systemic toxicity: may occur after overdose, rapid absorption, repeated dosing, or intravascular injection.
• Early toxicity signs: metallic taste, circumoral numbness, tongue numbness, tinnitus, dizziness, agitation, confusion, visual disturbance, tremor, or slurred speech.
• Severe toxicity: seizures, reduced consciousness, respiratory depression, arrhythmia, hypotension, cardiovascular collapse, or cardiac arrest.
• Epinephrine effects: palpitations, tremor, anxiety-like feeling, increased heart rate, increased blood pressure, or headache may occur, especially after intravascular injection.
• Paresthesia concern: persistent numbness or altered sensation has been reported with dental local anesthetics and should be documented and followed up.
• Cardiovascular caution: use the smallest effective epinephrine dose in patients with significant heart disease or unstable blood pressure.
• Children and low body weight adults: because articaine is usually 4%, fewer cartridges may reach the maximum dose.

Articaine 4% contains about twice as much anesthetic per milliliter as lidocaine 2%. This does not mean it is unsafe; it means the dentist must calculate the total milligram dose carefully, especially in small adults, children, older adults, and medically compromised patients.

• Other local anesthetics: total local anesthetic dose is additive and increases toxicity risk.
• Nonselective beta-blockers: may increase hypertensive response to epinephrine.
• Tricyclic antidepressants: may increase cardiovascular response to epinephrine.
• MAO inhibitors: may increase pressor response risk with sympathomimetic agents.
• Certain antipsychotics: may alter blood pressure response to epinephrine.
• Antiarrhythmic drugs: may increase cardiac conduction or rhythm concerns with local anesthetic or epinephrine exposure.
• Cocaine or stimulant use: can significantly increase cardiovascular risk when combined with epinephrine.
• Sedatives or general anesthetics: may change monitoring needs and respiratory/cardiovascular safety planning.

• Temporary numbness of lip, cheek, tongue, or soft tissues
• Injection-site pain, bruising, or hematoma
• Palpitations, tremor, anxiety-like feeling, or temporary increased heart rate from epinephrine
• Dizziness or lightheadedness, sometimes related to anxiety or vasovagal reaction
• Headache or mild blood pressure change
• Rare allergy or sulfite sensitivity reaction
• Persistent numbness, tingling, or altered sensation requiring follow-up
• Rare but serious: seizure, arrhythmia, respiratory depression, cardiovascular collapse, severe systemic toxicity
• Post-anesthetic lip, cheek, or tongue biting injury

• Do not chew food until the numbness has worn off to avoid biting the lip, cheek, or tongue.
• Children should be supervised while numb because they may bite or suck numb tissues.
• A temporary racing-heart or shaky feeling can happen after epinephrine, but severe symptoms should be reported immediately.
• Tell the dentist about heart disease, high blood pressure, arrhythmias, thyroid disease, pregnancy, stimulant use, and all medications.
• Report previous reactions to dental anesthesia, including fainting, palpitations, rash, swelling, persistent numbness, or breathing difficulty.
• Seek urgent help for breathing difficulty, facial swelling, throat swelling, severe dizziness, seizure, chest pain, or collapse.
• Contact the clinic if numbness lasts unusually long, altered sensation persists, swelling worsens, severe pain develops, or infection signs appear.

Articaine can be excellent for dental infiltration anesthesia, but its 4% concentration makes dose awareness essential. A useful habit is to say the dose out loud mentally: one 1.8 mL cartridge equals about 72 mg. This prevents the common mistake of thinking all dental cartridges carry the same milligram load.

• Metallic taste, circumoral numbness, tinnitus, visual disturbance, agitation, confusion, tremor, slurred speech, or seizure after injection
• Severe dizziness, fainting, collapse, or altered consciousness
• Chest pain, severe palpitations, severe hypertension symptoms, or irregular heartbeat
• Difficulty breathing, wheezing, facial swelling, throat swelling, or suspected allergic reaction
• Persistent numbness, tingling, altered sensation, or neurologic symptoms after anesthesia
• Uncontrolled bleeding, expanding hematoma, or rapidly increasing swelling
• Numbness lasting far longer than expected with functional problems
• Any suspected local anesthetic systemic toxicity requiring emergency management

• Lidocaine + Epinephrine
• Mepivacaine
• Prilocaine
• Bupivacaine + Epinephrine
• Epinephrine / Adrenaline
• Felypressin
• Topical lidocaine
• Lipid emulsion therapy for severe local anesthetic systemic toxicity

Articaine with epinephrine is a widely used dental local anesthetic combination for infiltration anesthesia, supplemental mandibular anesthesia, nerve blocks, endodontics, extractions, periodontal care, and minor oral surgery. It is often effective because of its diffusion properties and epinephrine-assisted duration and hemostasis. Safe use depends on patient assessment, milligram-based dose calculation, aspiration, slow injection, awareness of epinephrine interactions, recognition of toxicity signs, and follow-up of persistent altered sensation. The key dental habit is to remember that a 4% articaine cartridge carries about 72 mg in 1.8 mL.